GleamWall
中文EN

IDXG INTERPACE BIOSCIENCES, INC.

Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1054102 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-9.7%
TTM net income YoY355.8%
TTM EPS YoY217.6%
Revenue 3-yr CAGR-12.3%
Net income 3-yr CAGR—

Margins

Gross margin65.6%
Operating margin1.6%
Net margin58.1%
FCF margin7.6%
EBITDA margin3.0%

Returns

ROE179.8%
ROA88.6%
ROIC (approx.)6.2%
Asset turnover1.53x

Leverage & solvency

Liabilities / assets34.1%
Debt / equity0.00x
Current ratio2.06x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.16x
Accruals ratio74.5%
Payout ratio—
Capex / revenue1.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$38.73M$46.93M
Cost of revenue$14.60M$17.00M
Gross profit$24.13M$29.93M
R&D expense$642,000$676,000
SG&A expense$9.48M$9.49M
Operating income$4.08M$8.11M
Pretax income$3.77M$6.95M
Income tax-$21.21M$4,000
Net income$24.57M$6.70M
EBITDA$4.51M$8.41M
EPS (basic)5.551.42
EPS (diluted)0.890.40
Weighted avg. shares (diluted)27.70M15.73M
Balance sheet
Cash & equivalents$2.50M$1.46M
Receivables$5.65M$8.54M
Inventory$1.11M$1.21M
Current assets$9.90M$11.77M
PP&E, net$1.42M$1.36M
Total assets$33.84M$14.79M
Current liabilities$5.10M$10.62M
Total liabilities$11.47M$17.01M
Shareholders' equity$22.36M-$2.22M
Shares outstanding885,7084.41M
Cash flow statement
Operating cash flow$5.83M$4.65M
Capital expenditure$356,000$876,000
Free cash flow$5.47M$3.77M
Investing cash flow-$356,000-$876,000
Financing cash flow-$4.43M-$5.81M
Depreciation & amortization$425,000$300,000
Stock-based compensation$35,000$291,000

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.